WO2016120647A2 - Régénération musculaire - Google Patents
Régénération musculaire Download PDFInfo
- Publication number
- WO2016120647A2 WO2016120647A2 PCT/HU2015/050019 HU2015050019W WO2016120647A2 WO 2016120647 A2 WO2016120647 A2 WO 2016120647A2 HU 2015050019 W HU2015050019 W HU 2015050019W WO 2016120647 A2 WO2016120647 A2 WO 2016120647A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gdf3
- muscle
- ppary
- mos
- differentiation
- Prior art date
Links
- 230000009756 muscle regeneration Effects 0.000 title description 65
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 claims abstract description 225
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 claims abstract description 222
- 210000002540 macrophage Anatomy 0.000 claims abstract description 191
- 210000003205 muscle Anatomy 0.000 claims abstract description 176
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 144
- 230000014509 gene expression Effects 0.000 claims abstract description 106
- 230000004069 differentiation Effects 0.000 claims abstract description 70
- 210000003098 myoblast Anatomy 0.000 claims abstract description 66
- 238000011069 regeneration method Methods 0.000 claims abstract description 46
- 230000008929 regeneration Effects 0.000 claims abstract description 45
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 230000001771 impaired effect Effects 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims description 77
- 230000006378 damage Effects 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 13
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 208000021642 Muscular disease Diseases 0.000 claims description 10
- 102000048971 human GDF3 Human genes 0.000 claims description 8
- 201000009623 Myopathy Diseases 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000003387 muscular Effects 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 35
- 230000017423 tissue regeneration Effects 0.000 abstract description 16
- 239000012636 effector Substances 0.000 abstract description 10
- 230000024245 cell differentiation Effects 0.000 abstract description 6
- 210000000130 stem cell Anatomy 0.000 abstract description 5
- 108010016731 PPAR gamma Proteins 0.000 abstract description 3
- 102000043168 TGF-beta family Human genes 0.000 abstract description 3
- 108091085018 TGF-beta family Proteins 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 102000000536 PPAR gamma Human genes 0.000 abstract description 2
- 101150023417 PPARG gene Proteins 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 91
- 230000001105 regulatory effect Effects 0.000 description 58
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 47
- 239000002340 cardiotoxin Substances 0.000 description 47
- 231100000677 cardiotoxin Toxicity 0.000 description 47
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 41
- 208000027418 Wounds and injury Diseases 0.000 description 35
- 238000010322 bone marrow transplantation Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 208000014674 injury Diseases 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 33
- 239000003623 enhancer Substances 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 30
- 230000001172 regenerating effect Effects 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 230000001419 dependent effect Effects 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 23
- 230000033228 biological regulation Effects 0.000 description 22
- 230000008439 repair process Effects 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 239000003446 ligand Substances 0.000 description 21
- 229960004586 rosiglitazone Drugs 0.000 description 21
- 210000001185 bone marrow Anatomy 0.000 description 20
- 239000003636 conditioned culture medium Substances 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 230000002950 deficient Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 18
- 208000029549 Muscle injury Diseases 0.000 description 18
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000007812 deficiency Effects 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 210000001087 myotubule Anatomy 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 102000009618 Transforming Growth Factors Human genes 0.000 description 15
- 108010009583 Transforming Growth Factors Proteins 0.000 description 15
- 230000000242 pagocytic effect Effects 0.000 description 14
- 238000003559 RNA-seq method Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 13
- 206010057249 Phagocytosis Diseases 0.000 description 12
- 101000929049 Xenopus tropicalis Derriere protein Proteins 0.000 description 12
- 230000008782 phagocytosis Effects 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000008595 infiltration Effects 0.000 description 11
- 238000001764 infiltration Methods 0.000 description 11
- 230000002757 inflammatory effect Effects 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 11
- 238000010166 immunofluorescence Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 108010038912 Retinoid X Receptors Proteins 0.000 description 9
- 102000034527 Retinoid X Receptors Human genes 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000003076 paracrine Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 108010059616 Activins Proteins 0.000 description 7
- 241000283073 Equus caballus Species 0.000 description 7
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 102000040945 Transcription factor Human genes 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 7
- 239000000488 activin Substances 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000001338 necrotic effect Effects 0.000 description 7
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 102100026818 Inhibin beta E chain Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000003292 diminished effect Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 5
- 102100036912 Desmin Human genes 0.000 description 5
- 108010044052 Desmin Proteins 0.000 description 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 101100175312 Homo sapiens GDF3 gene Proteins 0.000 description 5
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 5
- 108010056852 Myostatin Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229940112869 bone morphogenetic protein Drugs 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 210000005045 desmin Anatomy 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 230000001114 myogenic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 4
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 description 4
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 206010028289 Muscle atrophy Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001447 compensatory effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010208 microarray analysis Methods 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 201000000585 muscular atrophy Diseases 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101150046085 INHBA gene Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 208000006541 Klippel-Feil syndrome Diseases 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101150014691 PPARA gene Proteins 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000037257 muscle growth Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000009711 regulatory function Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- 101150054149 ANGPTL4 gene Proteins 0.000 description 2
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100029952 Double-strand-break repair protein rad21 homolog Human genes 0.000 description 2
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 2
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 101000920778 Homo sapiens DNA excision repair protein ERCC-8 Proteins 0.000 description 2
- 101000584942 Homo sapiens Double-strand-break repair protein rad21 homolog Proteins 0.000 description 2
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 2
- 101000996034 Homo sapiens Nodal homolog Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- 102100034457 Nodal homolog Human genes 0.000 description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 108010023079 activin B Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000868 anti-mullerian hormone Substances 0.000 description 2
- 229930185229 antidesmin Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 108010045512 cohesins Proteins 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 201000009338 distal myopathy Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000007045 gastrulation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940071127 thioglycolate Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 101150087690 ACTB gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 241000282452 Ailuropoda melanoleuca Species 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 102100030685 Alpha-sarcoglycan Human genes 0.000 description 1
- 241001502973 Aotus nancymaae Species 0.000 description 1
- 241000579144 Apaloderma vittatum Species 0.000 description 1
- 241000511228 Austrofundulus limnaeus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283254 Balaenoptera acutorostrata Species 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 102100022546 Bone morphogenetic protein 8A Human genes 0.000 description 1
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
- 241001247317 Bos mutus Species 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 241000747063 Buceros rhinoceros silvestris Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101150112561 CD36 gene Proteins 0.000 description 1
- 241000288950 Callithrix jacchus Species 0.000 description 1
- 241000251191 Callorhinchus milii Species 0.000 description 1
- 102100029383 Calpain small subunit 2 Human genes 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241001263020 Ceratotherium simum simum Species 0.000 description 1
- 241000282556 Cercocebus atys Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 241001481771 Chinchilla lanigera Species 0.000 description 1
- 241001116820 Chlamydotis macqueenii Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 241001100448 Chrysochloris asiatica Species 0.000 description 1
- 241000385067 Colobus angolensis palliatus Species 0.000 description 1
- 241001282194 Condylura cristata Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241001014350 Cynoglossus semilaevis Species 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000289661 Dasypus novemcinctus Species 0.000 description 1
- 101100064517 Drosophila melanogaster Dlc90F gene Proteins 0.000 description 1
- 241000288717 Echinops telfairi Species 0.000 description 1
- 241001137323 Elephantulus edwardii Species 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 102100034239 Emerin Human genes 0.000 description 1
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283069 Equus przewalskii Species 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000277342 Esox lucius Species 0.000 description 1
- 241000531791 Eurypyga helias Species 0.000 description 1
- 101150018889 FABP4 gene Proteins 0.000 description 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 241000276423 Fundulus heteroclitus Species 0.000 description 1
- 101150019176 GDF10 gene Proteins 0.000 description 1
- 241000205692 Galeopterus variegatus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 description 1
- 208000015752 Growth delay due to insulin-like growth factor type 1 deficiency Diseases 0.000 description 1
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 101710204273 Growth/differentiation factor 3 Proteins 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 1
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 1
- 102100035970 Growth/differentiation factor 9 Human genes 0.000 description 1
- 241000276688 Haplochromis burtoni Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000703500 Homo sapiens Alpha-sarcoglycan Proteins 0.000 description 1
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 description 1
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 1
- 101000899364 Homo sapiens Bone morphogenetic protein 8A Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101000919200 Homo sapiens Calpain small subunit 2 Proteins 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 description 1
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 1
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 1
- 101001075110 Homo sapiens Growth/differentiation factor 9 Proteins 0.000 description 1
- 101001046599 Homo sapiens Krueppel-like factor 15 Proteins 0.000 description 1
- 101000903887 Homo sapiens Protein BEX1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000167869 Ictidomys tridecemlineatus Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108700038030 Insulin-Like Growth Factor I Deficiency Proteins 0.000 description 1
- 102100022328 Krueppel-like factor 15 Human genes 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 241001596950 Larimichthys crocea Species 0.000 description 1
- 241000251465 Latimeria chalumnae Species 0.000 description 1
- 102000002092 Left-Right Determination Factor Human genes 0.000 description 1
- 108050009437 Left-Right Determination Factor Proteins 0.000 description 1
- 241000283131 Leptonychotes weddellii Species 0.000 description 1
- 241001131651 Leptosomus discolor Species 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- 241000249820 Lipotes vexillifer Species 0.000 description 1
- 241000283093 Loxodonta africana Species 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282561 Macaca nemestrina Species 0.000 description 1
- 241000282532 Mandrillus leucophaeus Species 0.000 description 1
- 241001528492 Maylandia zebra Species 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241001416539 Microcebus murinus Species 0.000 description 1
- 241001327088 Microtus ochrogaster Species 0.000 description 1
- 241000500121 Mirax Species 0.000 description 1
- 241000736257 Monodelphis domestica Species 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 101100390735 Mus musculus Figla gene Proteins 0.000 description 1
- 101100175313 Mus musculus Gdf3 gene Proteins 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 241000287143 Myotis davidii Species 0.000 description 1
- 241000608621 Myotis lucifugus Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 241000649138 Nannospalax galili Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000882862 Nomascus leucogenys Species 0.000 description 1
- 241000269862 Notothenia coriiceps Species 0.000 description 1
- 241000283965 Ochotona princeps Species 0.000 description 1
- 241000700124 Octodon degus Species 0.000 description 1
- 206010052181 Oculopharyngeal dystrophy Diseases 0.000 description 1
- 241000283214 Odobenus rosmarus divergens Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 241000276703 Oreochromis niloticus Species 0.000 description 1
- 241000370375 Orycteropus afer afer Species 0.000 description 1
- 241000276569 Oryzias latipes Species 0.000 description 1
- 241001416563 Otolemur garnettii Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282576 Pan paniscus Species 0.000 description 1
- 241001278385 Panthera tigris altaica Species 0.000 description 1
- 241000609816 Pantholops hodgsonii Species 0.000 description 1
- 241000282516 Papio anubis Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000283222 Physeter catodon Species 0.000 description 1
- 241000231623 Poecilia formosa Species 0.000 description 1
- 241000276427 Poecilia reticulata Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000212139 Propithecus coquereli Species 0.000 description 1
- 102100024042 Protein BEX1 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000915511 Pteropus vampyrus Species 0.000 description 1
- 241000905728 Pundamilia nyererei Species 0.000 description 1
- 101150024504 Ramp3 gene Proteins 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 241000881856 Rhinopithecus roxellana Species 0.000 description 1
- 241001125016 Saimiri boliviensis Species 0.000 description 1
- 241000289607 Sarcophilus harrisii Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000143991 Sorex araneus Species 0.000 description 1
- 241001288662 Stegastes partitus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101150093886 TGFBR2 gene Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000593405 Trichechus manatus latirostris Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241001033908 Tupaia chinensis Species 0.000 description 1
- 241000283293 Tursiops Species 0.000 description 1
- 241001147416 Ursus maritimus Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101100175314 Xenopus laevis gdf3 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- -1 cysteine amino acids Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000020619 endoderm development Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000006277 exogenous ligand Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016208 familial periodic paralysis Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000023168 in utero embryonic development Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003847 mesoderm development Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008910 negative regulation of myoblast differentiation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 102000027507 nuclear receptors type II Human genes 0.000 description 1
- 108091008686 nuclear receptors type II Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000028926 regulation of MAPK cascade Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 108020001568 subdomains Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000035903 transrepression Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11013—Protein kinase C (2.7.11.13)
Definitions
- the present invention relates to the field of muscle regeneration.
- Tissues suffer physical and biochemical damage during an organism's lifetime. In order to maintain the body's integrity and homeostasis, it is critically important to completely regenerate [ad integrum) bodily damage. Certain organs, such as skeletal muscle, possess excellent regenerative potential by which a complete regeneration is possible. In many cases a straightforward paradigm can be applied to these regenerative processes whereby organ injury induces expansion and differentiation of a quiescent population of tissue-specific stem cell-like progenitors. Strikingly, the immune system has an indispensible role in tissue regeneration.
- Impaired injury -related immune response has been shown to greatly influence regeneration in a wide variety of organs, including liver, central nervous system or skeletal muscle (Chazaud, 2014; Duffield et al., 2005; Laflamme and Murry, 2011; Rapalino et al., 1998).
- immune cells and in particular MOs have a dual role during damage and regeneration.
- these cells need to react to the injury, remove damaged tissues and in the second phase, initiate restoration of tissue integrity via promoting repair mechanisms. It can be presumed that during this latter phase the immune response to tissue injury regulates the reengagement of tissue progenitor cell populations to support cellular growth and differentiation.
- skeletal muscle injury is a rapid but precisely timed and tightly regulated process in which a complete restoration of muscle structure can be achieved within weeks of an almost complete destruction of the tissue.
- Third, many aspects of skeletal muscle development and regeneration are well understood and can be studied in vitro (Yin et al., 2013). Several attempts have been made to treat muscle related disorders.
- growth and differentiation factor-8 also known as myostatin
- myostatin is a member of the transforming growth factor-beta (TGF-0 superfamily of structurally related growth factors, all of which possess important physiological growth-regulatory and morphogenetic properties) is a negative regulator of skeletal muscle mass, and there is considerable interest in identifying factors which regulate its biological activity.
- WO2003072715 relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8).
- the invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial.
- WO2008030706 among other similar publications relates to anti-myostatin monoclonal antibodies that preferentially bind myostatin (GDF-8) over GDF-11 and are resistant to protein cleavage, and use of the antibodies for treatment, prophylaxis or diagnosis of various disorders or conditions in mammalian and avian species.
- WO2010083034A1 discloses that ActRIIB (and its fusion proteins) can be used to increase circulating adiponectin levels in mouse models. Therefore, ActRIIB-derived agents can be used to treat or prevent hypoadiponectinemia. ActRIIB also has been identified as a type II serine/threonine kinase receptor (required for binding ligands and for expression of type I receptor) for activins and several other TGF-beta family proteins including GDF3 (mentioned in line with GDF8, i.e. myostatin), with which it can biochemically interact as a ligand. Thus, WO2010083034A1 disclosed that such ActRIIB-ligands, like GDF3 should be antagonized.
- WO2014000042A1 relates to an endogenous activin A and/or activin B activity suppressor propeptide or nucleic acid is useful in composition, preferably pharmaceutical composition for treating or preventing activin-induced muscle wasting, cachexia-anorexia syndrome and conditions induced or exacerbated by over expression of active TGF- ⁇ family ligands chosen from activin B, activin A, activin C, activin E, bone morphogenetic protein 7 (BMP7), BMP5, BMP6, BMP8A, BMP8B, BMP2, BMP4, BMP10, growth differentiation factor 2 (GDF2), GDF5, GDF6, GDF7, BMP3, BMP3B, left-right determination factor (lefty) 1 , lefty2, GDF1 , GDF3, nodal growth differentiation factor (NODAL), BMP 15, GDF9, GDF 15, mullerian inhibiting substance (MIS) and inhibin, and in therapy.
- active TGF- ⁇ family ligands chosen from activin B, activin A,
- the invention relates to a GDF3 compound for use in the treatment of a patient having a condition/disease associated with impaired muscle (def) and said patient being in need of muscle differentiation (def).
- the muscle differentiation comprises the differentiation of myoblasts (def) to myotubes (myotube differentiation (def)).
- the muscle differentiation is myotube differentiation.
- impaired muscle includes impaired muscle structure and/or impaired muscle function.
- impaired muscle in particular, in the impaired muscle there is a need of myotube formation.
- undifferentiated myoblasts are present (detection).
- the invention relates to a GDF3 compound for use in improving regeneration or differentiation of muscle of a patient in need thereof.
- the invention relates to a use of GDF3 for improving muscle regeneration in a condition/disease that is characterized by a failure in muscle regeneration.
- the invention relates to GDF3 for use in improving regeneration in muscle.
- the muscle is skeletal muscle.
- the muscle comprises undifferentiated myoblasts.
- the patient is a mammal, optionally a human.
- said impaired muscle is due to or associated with a condition/disease selected from the group consisting of
- myopathies preferably selected from myopathies caused by an inflammatory condition, a viral or bacterial infection, biologically active compounds like medicaments, toxins, etc., myopathies associated with systemic disorders, myopathies caused by genetic disorders, preferably muscular distrophies, sarcopenia, muscular atrophia,
- muscular dystrophy selected from Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-Girdle muscular dystrophy, Myotonic muscular dystrophy, Oculopharyngeal muscular dystrophy,
- muscle injury selected from an injury due to a toxin (def), impaired supply of the muscle, such as hypoxia or hypoglycaemia or impaired blood supply, a functional muscle injury e.g. increased muscle tone, a structural muscle injury characterized by strained or pulled muscle, (i.e. when muscle is overstretched or torn), etc.
- a toxin def
- impaired supply of the muscle such as hypoxia or hypoglycaemia or impaired blood supply
- a functional muscle injury e.g. increased muscle tone
- a structural muscle injury characterized by strained or pulled muscle i.e. when muscle is overstretched or torn
- a GDF3 compound is a compound comprising or consisting essentially of GDF3.
- the GDF3 compound is a recombinant GDF3 compound.
- the GDF3 compound is a wild type GDF3 compound.
- the recombinant or wild type GDF3 is a mammalian GDF3, optionally a human GDF3.
- the origin of GDF3 is the same species as that of the patient.
- the GDF3 compound is a mutant GDF3 compound (a mutant variant of a wild type GDF3).
- GDF3 is a mutant variant of a wild type GDF3 the sequence of which is at least 70%, 80% or at least 90% identical with a wild type GDF3, preferably a mammalian, optionally a human GDF3. (As to exemplary sequences of wild type GDF3 see Table 1).
- GDF3 is a fragment of a wild type GDF3 the length of which is at least 70%, 80% or at least 90% of that of a wild type GDF3, preferably a mammalian, optionally a human GDF3.
- GDF3 is a mutant variant of a fragment of a wild type GDF3 the sequence of which is at least 70%, 80% or at least 90% identical with that of the corresponding fragment of the wild type GDF3, preferably a mammalian, optionally a human GDF3, based on a sequence alignment including any accepted sequence alignment method.
- the recombinant or mutant or fragment maintains the fold of a wild type GDF3 compound.
- the invention relates to a pharmaceutical composition for any use as defined above said composition comprising a GDF3 compound as an active ingredient.
- the pharmaceutical composition comprises a GDF3 compound and is formulated for administration of GDF3 to the muscle, preferably to the impaired muscle as a target site.
- the invention relates to a pharmaceutical composition for any use as defined above said composition comprising a GDF3 expression construct as an active ingredient.
- the GDF3 expression construct is useful for expressing GDF3 in mammalian immune cells.
- the pharmaceutical composition comprises a manipulated macrophage overexpressing GDF3.
- the invention also relates to a method of treatment of a patient in a condition or disease as defined above, said method comprising the step of administration of GDF3 to said patient in an effective amount.
- the GDF3 compound is administered systemically.
- the GDF3 compound is administered locally to the impaired muscle.
- a macrophage overexpressing a GDF3 compound is administered locally to the impaired muscle.
- the present application also relates to methods for gene therapy.
- GDF3 as a natural molecule, is a member of the bone morphogenetic protein (BMP) family and the TGF- beta superfamily.
- BMP bone morphogenetic protein
- Mammalian, including human variants of the gene product (full length GDF3) comprise a signal peptide and a propeptide which are cleaved off during proteolytic processing at proteolytic processing sites, said signal peptide and propeptide being is cleaved off to produce a mature protein containing seven conserved cysteine residues forming three conserved disulphide bridges in the mature peptide fold.
- the members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues.
- the full length GDF3 in humans is 364 amino acids long wherein the signal peptide consists of amino acids 1 to 24 and the propeptide amino acids 25 to 250. In humans, amino acids 251 to 364 form the mature peptide.
- the full length GDF3 comprises two N-glycosylation sites at positions 112 and 306, i.e. the mature peptide comprises a single glycosylation site at position 306 (full length numbering).
- the mature peptide comprises three disulphide bonds, which are positioned in the human sequence between cysteine amino acids at positions 264 and 329, positions 293 and 361 and positions 297 and 363; or positions equivalent thereto in any vertebrate or preferably mammalian sequence. Unless indicated differently in case of natural variants the sequence numbering follows the numbering of the full length peptide sequence, preferably according to the human sequence.
- GDF3 or "GDF3 protein” refer herein to a protein encoded by the gdf3 gene of a vertebrate, preferably a mammal, or a processed form thereof.
- Said “GDF3” or “GDF3 protein” has preferably the sequence of any natural variant of a vertebrate, preferably mammalian species, said variant having a GDF3 activity.
- Preferably said "GDF3” or “GDF3 protein” comprises the sequence of a mature peptide fragment wherein the GDR3 signal peptide and propeptide have been cleaved.
- GDF3 or “GDF3 protein” include protein fragments, variants and variants of fragments (fragment variants) having GDF-3 activity, preferably said variants or fragments or fragment variants having a sequence having at least 70%, at least 80% or at least 90% identity with a corresponding portion of a natural variant, preferably a natural mature peptide, said fragments or fragment variant having a length of at least 80 or 90 or 100 or 110 amino acids and at most 115 or 120 or 130 or 140 or 150 amino acids, preferably 80 to 150 or 90 to 140 or 100 to 130 or 110 to 120 amino acids.
- the length of the mature peptide is about 112, 113, 114, 115, 116, 117 or 118 amino acids.
- the terms include the full length unprocessed precursor form of the protein, as well as the propeptide-linked and mature forms resulting from post-translational cleavage.
- the terms also refer to any fragments of GDF3 that maintain the known biological activities associated with the protein, including sequences that have been modified with conservative or non-conservative changes to the amino acid sequence.
- GDF3 molecules according to the invention may be derived from any source, e.g. natural, recombinant or synthetic.
- the protein may be human or derived from animal sources, in particular from vertebrates, including bovine, chicken, murine, rat, porcine, ovine, turkey, baboon, and fish. Mammalian sources are preferred.
- variant GDF3 molecule refers herein to a molecule which differs in amino acid sequence from a natural GDF3 molecule by virtue of addition, deletion and/or substitution of one or more amino acid residue(s) in the parent GDF3.
- the variant GDF3 comprises one or more amino acid substitution (s) in the mature peptide part of GDF3.
- a variant may be a natural variant or an artificial variant, wherein the amino acid sequence of the latter does not occur in nature.
- Micromature GDF3 refers to the protein that is cleaved from the carboxy-terminal domain of the GDF3 precursor protein.
- GDF3 propeptide refers to the polypeptide that is cleaved from the amino-terminal domain of the GDF3 precursor protein.
- the GDF3 propeptide is capable of binding to the propeptide binding domain on the mature GDF-8.
- GDF3 activity refers to one or more of physiological function associated with active GDF3 protein.
- Biological functions of GDF3 identified so far can be selected from the group of functions listed herein: BMP signaling pathway, cell development, endoderm development, formation of anatomical boundary, in utero embryonic development, mesoderm development, regulation of apoptotic process, regulation of MAPK cascade etc.
- isolated refers to a molecule that is substantially free of its natural environment.
- an isolated protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which it is derived.
- substantially purified or purified refers to preparations where the isolated protein is at least 70% to 80% (w/w) pure, at least 80%-89% (w/w) pure, at least 90-95% pure, or at least 96%, 97%, 98%, 99% or 100% (w/w) pure.
- treating refers to both therapeutic treatment and prophylactic treatment such as prevention.
- Those in need of treatment may include subjects already having a particular medical disorder as well as those who may ultimately acquire the disorder (i.e., those needing preventative measures).
- treatment in a broader sense includes both measures that address the underlying cause of a disorder and measures that reduce symptoms of a medical disorder without necessarily affecting its cause.
- muscle disorder refers herein in particular to disorders of muscle, in particular disorders associated with muscle differentiation.
- disorders may be, among others, muscle and neuromuscular disorders such as muscular dystrophy (including but not limited to severe or benign X-linked muscular dystrophy, limb-girdle dystrophy, facioscapulohumeral dystrophy, myotinic dystrophy, distal muscular dystrophy, progressive dystrophic ophthalmoplegia, oculopharyngeal dystrophy, Duchenne's muscular dystrophy (including but not limited to severe or benign X-linked muscular dystrophy, limb-girdle dystrophy, facioscapulohumeral dystrophy, myotinic dystrophy, distal muscular dystrophy, progressive dystrophic ophthalmoplegia, oculopharyngeal dystrophy, Duchenne's muscular dystrophy (including but not limited to severe or benign X-linked muscular dystrophy, limb-girdle dystrophy, facio
- P117750 dystrophy and Fakuyama-type congenital muscular dystophy; amyotrophic lateral sclerosis (ALS); muscle atrophy; frailty; congenital myopathy; myotonia congenital; familial periodic paralysis; myasthenia gravis; Eaton-Lambert syndrome; secondary myasthenia; paroxymal muscle atrophy; and sarcopenia, cachexia and other muscle wasting syndromes.
- ALS amyotrophic lateral sclerosis
- terapéuticaally effective refers to a treatment which results in improvement of symptoms of a disorder, a slowing of the progression of a disorder, or a cessation in the progression of a disorder.
- the therapeutic benefit is determined by comparing an aspect of a disorder, such as observation of muscle regeneration, differentiation of muscle cells, observation of inflammation, the amount of muscle mass, before and after GDF3 of the invention is administered.
- subject used interchangeably herein, refer to an animal, preferably a vertebrate species, more preferably mammalian (including a nonprimate and a primate) or avian species, including, but not limited to, murines, simians, humans, mammalian farm animals (e.g., bovine, porcine, ovine), mammalian sport animals (e.g., equine), and mammalian pets (e.g., canine and feline); preferably the term refers to humans.
- mammalian farm animals e.g., bovine, porcine, ovine
- mammalian sport animals e.g., equine
- mammalian pets e.g., canine and feline
- avian species including, but not limited to, chickens and turkeys.
- a "patient” is a subject who is a target of therapy.
- the subject preferably a mammal, more preferably a human, is further characterized with a disease or disorder or condition that would benefit from the administration of GDF3.
- the ..percent identity is the percent of amino acids or nucleobases in a first sequence (e.g. an original or a modified sequence) present in a second sequence (e.g. an original or a modified sequence) wherein the first sequence is aligned with the second sequence, and wherein, if after alignment any of the first or second sequence has an additional unaligned (overhanging) portion, then percent identity is defined for the aligned portions only wherein the reference sequence is the sequence having identical or more amino acids or nucleobases than the other sequence.
- a 30 amino acids or nucleobases long sequence comprising the full sequence of a sequence of interest (a modified sequence or in this case a fragment) of 20 amino acids or nucleobases long would have a portion of 100% identity with the sequence of interest, while further comprising an additional 10 amino acids or nucleobases portion.
- the sequence of interest has e.g. 2 or 4 amino acids or nucleobases mutated or deleted in comparison with the aligned portion of the reference sequence then the sequence of interest has a 90% or 80% identity, respectively, with the reference sequence.
- Fig. Number and fate of infiltrating cells in injured muscle. For gating strategy, see Fig S3.
- A Total number of infiltrating CD45+ hematopoietic cells (+/- SD) isolated from CTX injured muscles of WT and PPARg MacKO animals at day 1, day 2 and day 4.
- B Percentage of neutrophils and Ly6C+ MOs and the (C) calculated neutrophil and ⁇ numbers (derived from the % of the total numbers) at day 1 in injured muscles.
- D and E Percentage of Ly6C+ and Ly6C- MOs in injured muscles at day 2 and day 4.
- FIG. 1 Impact of PPARy on ⁇ functions
- A Experimental strategy to measure in vitro phagocytosis in BMDMs.
- B Percentage of phagocytic BMDMs and the Median Fluorescence Intensity (MFI) in the phagocytic BMDM compartment in BMDMs derived from WT vs. PPARg MacKO or WT BMT vs PPARg KO BMT animals.
- Fig 4. Transcriptional analysis of Ly6C+ and Ly6C- ⁇ populations derived from WT and PPARg MacKO animals. For schematics of comparisons, see Fig S4.
- (A) Heatmap representation of genes that show differential (p 0.05, min. 1.5X FC) expression in the four sorted WT vs PPARg MacKO MOs in day 1 Ly6C+ (labeled as D lLy6C+ etc.), D2 Ly6C+ and D2 Ly6C-, and D4 Ly6C- cells. In each heatmap, the differently expressed genes are highlighted within a red square and the expression pattern of these genes in the other macrophage subtypes is also shown for reference.
- GDF3 and Apoldl the genes that are down, - or upregulated in PPARg MacKOs in all four subtypes, are highlighted.
- C Venn diagramms showing the overlap of genes that are down-, or upregulated in PPARg MacKO MOs in the four analyzed MO subtypes.
- D Heatmap representation of the expression pattern of the genes that are RSG regulated in WT Ly6C- cells at day 2 in all isolated MO subtypes. Different Hist2h3 isoforms are labeled as histone genes.
- Gdf3 is a PPARy target gene in BMDMs
- B Identification of possible enhancers around the Gd/3 locus. The enhancer identification strategy around AngptI4 is shown in Fig S6A.
- GDF3 is a regulator of muscle regeneration.
- A Representative HE stained muscle sections of WT BMT and GDF3 KO BMT animals, 16 days post CTX injury.
- B Average myofiber CSA measurement in WT BMT and GDF3 KO BMT animals, 16 days post CTX injury.
- C Myofiber CSA repartition in WT BMT and GDF3 KO BMT animals at 16 days post CTX injury.
- D GDF3 protein expression in whole muscle lysates of regenerating WT muscles at different timepoints. For densitometric analyses, see Fig S7A and S7B. Specificity of the anti-GDF3 antibody is shown in Fig S7C.
- FIG. 1 in vitro proliferation (left panel) and differentiation (right panel) assays on primary myoblasts carried out with recombinant GDF3 reveal a pro-differentiation effect of GDF3 on muscle progenitor cells.
- B IF against desmin (red) and DAPI (blue) shows a drastic enhancement of myotube fusion in the presence of recGDF3 in in vitro primary myoblast differentiation assay
- C Heatmap representation of the expression pattern of selected genes validating the utilized in vitro primary differentiation myoblast assay
- D Heatmap representation of genes that are differently expressed (min.
- C Expression of Pparg mRNA in day 1 WT and day 2 WT or PPARg MacKO CD45+ cells and in (D) day 2 Ly6C+ and Ly6C- MOs isolated from CTX injured muscle.
- FIGS. Additional analysis of the impact of PPARy on muscle regeneration
- A Cumulative CSA analysis of muscle section derived from WT or PPARg MacKO animals at day 8 or day 21 post CTX injury.
- B IF of desmin (red), F4/80 (green) and DAPI (blue) on muscle sections from full body Pparg n l + , Sox2Cre- (controls) and Pparg ⁇ l-, Sox2Cre+ (KO) animals isolated at day 8 post CTX.
- Fig S5. mRNA expression of PPARy dependent genes in muscle derived sterile inflammatory MOs detected by RT-qPCR.
- FIG S6 Schematics of active enhancer identification
- A Identification of the active, PPARy regulated enhancer around the Angptl4 locus. Red vertical line labels the relevant enhancer.
- B Enhancer selection scheme for identifying active enhancers around the Gd/3 locus.
- Fig S7 Additional analysis of the expression of TGF family members in muscle and in muscle derived macrophages
- a and B Densitometric evaluation of GDF3 protein expression from western blots in Fig 6D and E, respectively.
- C Western blot detection of GDF3 in day 4 whole muscle lysates derived from WT and GDF3-/- animals show high specificity of the anti-GDF3 antibody.
- D List of members of the TGF family signaling system that are not expressed in muscle derived macrophages.
- CX cardiotoxin
- PPARy Peroxisome Proliferator-Activated Receptor gamma
- GDF3 a secreted factor
- our data reveal a novel integrated pathway with sensory, gene regulatory and effector components in which PPARy in repair MOs responds to signals and supports the timely promotion of tissue repair during muscle regeneration.
- our data also point to GDF3 as a repair ⁇ -derived novel pro-differentiation factor in muscle regeneration.
- the GDF3 ["growth differentiation factor 3"; also known as Vg-related gene 2 (Vgr-2), KFS3, MC0P7 or MC0PCB6] gene provides instructions for making a protein that is part of the transforming growth factor beta (TGFp) superfamily, which is a group of proteins that help control the growth and development of tissues throughout the body.
- TGFp transforming growth factor beta
- the GDF3 protein belongs to the bone morphogenetic protein family, which is involved in regulating the growth and maturation (differentiation) of bone and cartilage.
- Cartilage is a tough but flexible tissue that makes up much of the skeleton during early development.
- the proteins in this family are regulators of cell growth and differentiation in both embryonic and adult tissue.
- GDF3 While the GDF3 gene is known to be involved in bone and cartilage development, its exact role has been unclear [see Levine AJ, Brivanlou AH. GDF3 at the crossroads of TGF-beta signaling. Cell Cycle. 2006 May;5(10):1069-73. Epub 2006 May 15. Review]
- GDF3 a BMP inhibitor, regulates cell fate in stem cells and early embryos. Development 133 (2): 209-16.
- GDF3 gene mutations that cause Klippel-Feil syndrome lead to a change in single protein building blocks (amino acids) in the GDF3 protein. These mutations likely lead to a reduction in functional protein. While the GDF3 protein is involved in bone growth, it is unclear how a shortage in these proteins leads to incomplete separation of the vertebrae, specifically the cervical vertebrae, in people with Klippel-Feil syndrome.
- the GDF3 gene is located on the short (p) arm of chromosome 12 at position 13.1. More precisely, the GDF3 gene is located from base pair 7,689,784 to base pair 7,695,763 on chromosome 12.
- Rhinopithecus roxellana Rhinopithecus roxellana
- the sequence of human GDF3 is as follows (SEQ ID NO: 1):
- Tissue regeneration is an indispensable part of life that ensures survival.
- the involvement of MOs in tissue regeneration appears to be an evolutionary conserved process, as MOs provide critical functions in regeneration of zebrafish tail fin, salamander limb or neonatal heart as well as adult liver and skeletal muscle in mammals, among others (Chazaud, 2014; Godwin et al., 2013; Petrie et al., 2014; Porrello et al., 2011).
- MOs are infiltrating myeloid cells that are equipped with by an extensive range of cell surface and intracellular molecules that enable them not only to specifically sense and interpret the nature of the damage and also to monitor the progress of repair.
- MOs are transcriptionally plastic with the capacity to assume dramatically different cellular phenotypes depending on environmental cues (Kaikkonen et al., 2013; Lavin et al., 2014; Okabe and Medzhitov, 2014; Ostuni et al., 2013). These properties, along with the ability to secrete proteins, could enable MOs to orchestrate regenerative processes in a rapidly changing milieu of injured/regenerating tissues; however, the details of their supporting functions in regeneration have remained elusive. Particularly little is known about how MOs instruct myoblasts to form muscle fibers. We have identified the ligand activated transcription factor, PPARy, as a regulator of this process.
- PPARy ligand activated transcription factor
- MO PPARy-deficient animals As skeletal muscle possesses excellent regenerative capacity, it was especially interesting that the delay in muscle regeneration in MO PPARy-deficient animals was detectable as long as three weeks after the initial injury, well beyond the timeframe that is required to regenerate muscle structure.
- One of the best characterized genetic models for the involvement of MOs in muscle regeneration is the MO selective AMPK- deficient mouse, which exhibits a profound delay in muscle regeneration in the same experimental system (Mounier et al., 2013).
- the phenotype seen in the MO PPARy deficient mice was comparable in its extent to the delay reported in MO AMPK deficient animals, thus appearing to be among the most dramatic reported deficiencies caused by impairments in MO functions. This suggests that PPARy is likely to play an important and integrated sensory and regulatory function to synchronize cellular interactions during regeneration.
- P117750 as PPARy has been reported to be a regulator of ⁇ polarization (Odegaard et al., 2007). Either the Ly6C+ to Ly6C- ⁇ transition in this system does not correspond to canonical polarized ⁇ populations, or PPARy is not a critical component of alternatively polarized MOs in this setting. Phagocytosis was normal in PPARg MacKO MOs, and is therefore unlikely to explain the observed delay in regeneration. Systematic transcriptomic analyses, however, provided clues about both the sensory and the regulatory roles of PPARy in muscle infiltrating MOs.
- GDF3 is a strong candidate as a MO derived paracrine factor with muscle regenerative functions, whose diminished MO
- GDF3 protein expression peaked on day 4, at the time when the presumed switch from acute inflammation to active regeneration is completed in injured muscle and at the time of the beginning of myogenic precursor differentiation in vivo (Bentzinger et al., 2013; Parisi et al., 2015). It is noteworthy, that GDF3 expression at both the gene expression and protein levels was much lower in the CD45- fraction isolated from injured muscle than in the hematopoietic compartment. Considering that the separation of CD45+/- cells is inherently incomplete, our results indicate that MOs are the predominant, if not the only source of GDF3 within the injured tissue.
- ⁇ derived GDF3 is a tissue regeneration factor that regulates MPC expansion/differentiation within the injured tissue.
- recombinant GDF3 enhanced myotube fusion and in vitro differentiation of established primary myoblasts.
- GDF3 was added to independently isolated primary myoblast cell lines, excluding a cell line dependent effect.
- GDF3 regulated several genes whose functions are closely linked to muscle biology. Whether these genes are directly regulated by GDF3 or they were only markers of the enhanced differentiation, is presently unclear.
- GDF3 which is expressed in and secreted by muscle infiltrating MOs within injured and regenerating muscles has the capacity to elicit biologically relevant responses in primary myoblasts and differentiating myotubes and is a regulator of both in vitro muscle proliferation/differentiation and muscle regeneration in vivo.
- This regulatory axis consists of PPARy, a ligand activated transcription factor that appears to have distinct, but overlapping functions in the inflammatory and repair MOs within the injured tissue. PPARy then regulates muscle regeneration through the action of GDF3, a secreted factor that regulates MPC differentiation.
- GDF3 a secreted factor that regulates MPC differentiation.
- GDF3 is only one of the TGF family members that are active during regeneration and that it has effects on other cell types such as fibro/adipogenic progenitors as well (Hidestrand et al., 2008; Joe et al., 2010; Lemos et al., 2015). It is remarkable, though, that the key elements of the complex delay phenotype can be modeled in vitro using macrophages and myoblasts only, arguing that these two cell types and their interactions are critical to supporting regeneration. Irrespective of the answers to the questions above, our findings also carry potential implications for pathological circumstances in which recurrent muscle damage and asynchrony in repair due
- GDF3 is also a regulator of muscle regeneration in DMD or other types of myopathies, which are most of the time associated with the permanent presence of inflammatory cells, especially MOs.
- fusion proteins which also can be prepared for therapeutic purposes e.g. in Schmidt, Stefan R. (Editor) "Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges” ISBN: 978-0-470-64627-4, April 2013.
- the dosage regimen will be determined by the attending physician considering various factors which modify the action of the GDF-3 protein, e.g. amount of tissue desired to be formed, the site of tissue damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors.
- the dosage may vary with the type of matrix used in the reconstitution and the types of GDF3 compound.
- systemic or injectable administration such as intravenous (IV), intramuscular (IM) or subcutaneous (Sub-Q) injection are considered or used.
- Administration will generally be initiated at a dose which is minimally effective, and the dose will be increased over a preselected time course until a positive effect is observed.
- P117750 isolated representative ⁇ populations from injured muscle and interrogated their gene expression profiles by microarray analysis.
- an initial wave of Ly6C+ ⁇ infiltration is replaced by the emergence of Ly6C- MOs from day 2 on.
- the simplified, but widely accepted paradigm about these two main ⁇ populations posits that the Ly6C+ MOs are inflammatory, while Ly6C- MOs are repairing.
- the expression profiles of Ly6C+ inflammatory and Ly6C- repair MOs derived from injured muscle at day 2 CTX injury were compared, GO categories belonging to lipid and carbohydrate metabolism dominated the biological processes that were the most robustly upregulated with the transition to the Ly6C- (repair) MOs (Fig S1A).
- mice that received bone marrow deficient in PPARy exhibited a profound delay in regeneration. Similar to the delayed regeneration seen in the PPARg MacKO animals, muscle sections of PPARg KO BMT mice contained significantly more small myofibers, as demonstrated by the lower CSA (Fig IE and IF). Further underlying the importance of PPARy in muscle regeneration, full body PEl 131313 n _ Sox2 Cr e + animals displayed a drastic impairment in their skeletal muscle regeneration (Fig. S2B). Altogether, the results from these distinct genetic models clearly indicated that PPARy activity in muscle infiltrative MOs critically contributed to the timely resolution of inflammation and to regeneration.
- PPARy does not alter macrophage infiltration or differentiation in injured muscle
- P117750 injured muscle are neutrophils and Ly6C+ MOs.
- Ly6C mid F4/80 neutrophils and Ly6C + F4/80 low MOs within the CD45+ cells isolated from injured muscle at day 1 (Fig 2 B).
- Fig 2 B fewer neutrophils infiltrated the injured muscle in PPARg MacKO animals (68.05 % vs. 64 %), which also meant that the ratio of Ly6C+ MOs were slightly higher in PPARy deficient animals (19.4 % vs. 22.7 %).
- MOs have traditionally been considered to be primarily phagocytic cells. Therefore, one plausible explanation is that PPARy activity in MOs is required for the clearance of dying muscle tissue, and the failure of regeneration in PPARg MacKO animals is due to improper clearance of debris. While the importance of MOs in phagocytic clearance is beyond doubt, it recently became widely accepted that MOs could promote regeneration via other important functions apart from phagocytosis, such as the production of biologically active molecules [e.g. IGF1) that regulate muscle growth or differentiation (Tonkin et al., 2015).
- IGF1 biologically active molecules
- MO PPARy could plausibly improve the regenerative capacity of skeletal muscle by affecting MPC expansion or differentiation, independent of its phagocytic activity.
- BMDMs bone marrow derived MOs
- P117750 showed a slight, but not significant increase in the number of BMDMs that phagocytosed C2C12 cells when compared to WT BMDMs, indicating that PPARg KO BMDMs had a borderline increased propensity to engage in phagocytosis.
- the median fluorescence intensity of the BMDMs that took up C2C12 cell debris was not different between double positive BMDMs of WT or PPARg MacKO genotypes, indicating that once phagocytosis commenced, both cells were able to take up the same load of foreign material.
- conditioned medium from non-treated PPARg MacKO BMDMs phenocopied the proliferation enhancing effect of inflammatory WT BMDMs on myoblasts (Fig 3C).
- P117750 that were most differentially regulated in WT vs. PPARg MacKO cells are shown in Fig. 4B.
- the number of genes that were concordantly regulated in a PPARy mediated manner in more than one ⁇ subtypes is shown in Fig. 4C.
- Ly6C- MOs at day 2 express PPARy , but the receptor is also sensitive to the activating effect of an exogenous ligand in Ly6C- cells.
- Gd/3 the gene that was found to be consistently downregulated in PPARg MacKO MO subsets, was also regulated by RSG treatment in Ly6C- MOs. How can one reconcile the facts that only a few genes were differently expressed in Ly6C- cells, yet from a biased point of view based on literature data, this gene list seemed far the most likely reporter of the transcriptional response of synthetic ligand activation of PPARy in infiltrating MO subsets?
- GDF3 is a ⁇ derived PPARy dependent member of the TGFfi family
- Gd/3 was the top ranked gene (ranked by fold change difference) in 3 out of 4 MO subsets (Fig 4B).
- GDF3 belongs to the TGF family, whose members are secreted factors acting in a paracrine manner.
- GDF8 also known as Myostatin
- Gd/3 we selected Gd/3 as the most likely PPARy dependent gene that contributes to muscle regeneration for further analysis.
- BMDMs a readily available in vitro model system that allowed us to employ high- throughput genomic and epigenetic methods to interrogate the regulatory mechanism exerted by PPARy on the Gdf3 locus.
- WT and PPARy LysMCre BMDMs provided a platform with good correlation to study the PPARy dependent regulation of Gd/3, as PPARy deficiency in BMDMs abrogated the expression of both the canonical PPARy target gene AngptH and that of Gd/3 (Fig 5A).
- CTCF as a binding factor of insulator regions and RAD21, as a component of the cohesin complex to determine the genomic regulatory region and boundaries of potential chromatin loops/topological domains
- PU.l as a key lineage determining and proposed pioneering factor in MOs
- RXR the obligate heterodimeric partner of PPARy
- PPARy ChlP-seq data derived from thioglycolate elicited peritoneal MOs and adipocytes.
- Gdf3 was regulated by one or several of these PPARy:RXR binding sites.
- the binding sites at +7.3kb and -21kb contain bona fide DR-1 binding sites determined by the PPARy and RXR motif matrices of the HOMER database.
- the complexity of this locus and the number of binding sites detected call for more detailed analyses to uncover the contribution of the individual binding sites to the regulation.
- P117750 GDF3 is a regulator of myoblast proliferation, differentiation and muscle regeneration
- CD45+ cells which comprise all infiltrating hematopoietic cells within the injured tissue, expressed Gd/3 at much higher levels than CD45- (the non-hematopoietic cells in injured muscle) cells (Fig 6F). Accordingly, while the CD45+ compartments isolated from injured muscles showed robust GDF3 protein levels (Fig 6G), the expression was much lower in CD45- cells.
- GDF3 is a ⁇ derived protein whose expression is induced during muscle regeneration in a PPARy dependent manner.
- GDF3 a ⁇ derived secreted factor can regulate in vitro and in situ muscle differentiation/regeneration
- Fig 7E the transcriptomic features of muscle infiltrative MOs to chart the expression and dynamics of the TGF family signaling system (Fig 7E) to identify additional factors that might regulate regeneration in a paracrine or autocrine manner.
- P117750 ligands [Gdf3, Gdfl5 and Inhba) showed notable gene expression dynamics in muscle infiltrative MOs. GDF3 expression peaked in repair MOs and showed definitive, consistent regulation by PPARy. The two other family members, Gdfl5 and Inhba, were also regulated during muscle regeneration. Importantly, both genes exhibited partial PPARy dependency, but while Gdfl5 showed a similar expression pattern to that of Gd/3, expression of Inhba (activin ⁇ ) showed a temporary boost in its expression at the earliest stage of injury.
- the activin system has also been identified as a regulator of muscle growth or regeneration (Lach-Trifilieff et al., 2014; Yaden et al., 2014).
- Three non-ligand members of the TGF family signaling system, Tgfbr2, Eng and Bambi were also regulated in muscle MOs. Twelve other members of the signaling system were also expressed but not regulated in these MOs, while the remaining members (including myostatin) were not expressed at all (Fig S7D).
- the PPARy-GDF3 regulatory axis described in this study therefore identifies a sensory-regulatory-effector mechanism, by which MOs are regulators of the tissue progenitor compartment, namely MPCs. This axis orchestrates tissue regeneration, possibly in unison with other members of the TGF family, leading to synchronous regeneration.
- mice Ppar fl/flLysMCre+ (refered to as PPARg MacKO) and wild type C57BL/6J controls, Ppargfl/- Sox2Cre+ and littermate control PpargflZ+LysMCre- animals, and Gd/3 KO and littermate C57BL/6 albino controls were used in the experiments. All experimental procedure conducted on animals were carried out in accordance with institutional regulations.
- Muscle injury Mice were anaesthetized with isoflurane and 50 ⁇ of cardiotoxin (12X10-6 mol/1 in PBS) was injected in the tibialis anterior (TA) muscle. Muscles were recovered for flow cytometry analysis at day 1, 2 or 4 post-injury or for muscle histology at day 8 post-injury.
- HE stained sections were analyzed for cross sectional area (CSA) or for the presence of phagocytic fibers. Day 8 post CTX slides were also IF stained for Desmin / F4/80 / DAPI.
- Macrophage cell culture for conditioned medium generation Macrophages were obtained from bone marrow (BM) precursor cells that were were cultured in DMEM medium containing 20% FBS and 30% conditioned medium of L929 cell line 37 (enriched in CSF-1) for 7 days. Macrophages were activated with IFNy (50 ng/ml) or IL4 (10 ng/ml) to obtain macrophage-conditioned medium.
- BM bone marrow
- DMEM medium containing 20% FBS and 30% conditioned medium of L929 cell line 37 (enriched in CSF-1) for 7 days.
- Macrophages were activated with IFNy (50 ng/ml) or IL4 (10 ng/ml) to obtain macrophage-conditioned medium.
- MPC Myogenic precursor cell culture.
- Murine MPCs were obtained from TA muscle and cultured using standard conditions in DMEM/ F12 (Gibco Life Technologies) containing 20% FBS and 2% G/Ultroser (Pall Inc). For proliferation studies, MPCs were incubated for 1 day with conditioned medium + 2.5% FBS or with 2.5% FBS medium containing GDF3 mouse recombinant protein. Cells were then incubated with anti-DMEM/ F12 (Gibco Life Technologies) containing 20% FBS and 2% G/Ultroser (Pall Inc). For proliferation studies, MPCs were incubated for 1 day with conditioned medium + 2.5% FBS or with 2.5% FBS medium containing GDF3 mouse recombinant protein. Cells were then incubated with anti-
- P117750 ki67 antibodies (15580 Abeam), which were subsequently visualized using cy3-conjugated secondary antibodies (Jackson Immunoresearch Inc).
- MPCs were incubated for 3 days with conditioned medium containing 2% horse serum or with 2% horse serum medium containing GDF3. Cells were then incubated with anti-desmin antibodies (32362 Abeam), in combination with a cy3 -conjugated secondary antibody (Jackson Immunoresearch Inc).
- Phagocytosis assay BMDM cells and C2C12 cells were stained with CellVue or PKH67 (Sigma), respectively. Heat killed stained C2C12 were used as phagocytic substrates for stained BMDMs and fluorescent intensity was measured with a FACScalibur instrument.
- Fusion index for myogenic cells was calculated as the number of nuclei within myotubes divided by the total number of nuclei, nuclei number being estimated using the Image J software.
- CD45+ cells were isolated from CTX injected muscles using magnetic sorting (Miltenyi Biotec). CD45+ cells then were labeled with fluorescently labeled antibodies and Ly6C+ F4/801ow macrophages, Ly6C- F4/80+ macrophages and Ly6Cmid F4/80- neutrophils were analyzed and sorted with a BD FACSAria III sorter.
- RNA isolation from sorted MFs MF subsets were sorted from day 1, 2 and 4 post-injury muscles with a FACSAria III sorter and total RNA was isolated with TRIZOL reagent according to the manufacturer's recommendation.
- Microarray analysis of muscle macrophages Global expression pattern was analyzed on Affymetrix GeneChip Mouse Gene 1.0 ST arrays. The microarray data are publicly available (Data access: GSE71155).
- ChIP ChIP was carried out in BMDMs using antibodies against pre- immune IgG (Millipore, 12-370), (pan) RXR (sc-774 Santa Cruz Biotechnology) and PPARy (Perseus #PP- A3409A).
- Bioinformatic analysis of the active enhancers around the Gdf3 and AngptI4 locus The list of published and/or publicly available datasets used for visualization in IGV2 to identify active enhancers can be found in the supplememntal method section.
- GDF3 protein expression was measured using Western Blot analysis. Samples from CTX injected TA muscles or CD45+ cells were lysed in RIPA buffer. GDF3 was targeted using rabbit monoclonal Anti-GDF3 primary antibody (abl09617, Abeam, Cambridge, MA) at 1:1,000 dilution in 5% BSA/TBS-T overnight at 4°C. Anti-GAPDH mouse monoclonal primary antibody (AM4300, Ambion, Carlsbad, CA) was used as a protein loading control at 1:10,000 - 1:20,000 dilution in 5% BSA/TBST overnight at 4°C.
- Anti-GAPDH mouse monoclonal primary antibody AM4300, Ambion, Carlsbad, CA
- RNA sequencing (RNA-Seq) library preparation for myoblast gene expression analysis cDNA library for RNA-Seq was generated from ⁇ g total RNA using TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. The RNA-Seq data are publicly accessible (data access: PRJNA290560/SRR2136645).
- mice Genetically modified (floxed) PPARg conditional KO mice and wild type C57BL/6J controls were bred under SPF conditions and used for experiments in accordance with Hungarian (license no.: 21/2011/DE MAB) and European regulations. Experiments were conducted on adult (2-4 month old) male mice. Breeding of genetically modified Gd/3 KO and their control C57BL/6 albino animals, and the experiments with them were accepted and conducted with the permission of Sanford Burnham Prebys Medical Discovery Institute at Lake Nona IACUC approval (protocol No. 2014-0107).
- Ppar fl/flLysMCre+ (refered to as PPARg MacKO) (maintained on C57BL/6J background) and wild type C57BL/6J mice were used in most experiments. They were generated in Ppar5 , fl/flLysMCre+ X Ppar5 , fl/flLysMCre+ and WT X WT crossings. In a separate experiment, a small cohort of Ppar5 , fl/flLysMCre+ and littermate control Ppar5 , +/+LysMCre+ animals were generated from Ppar5 , fl/+LysMCre+ X Ppar5 , fl/+LysMCre+ crossings.
- Bone marrow transplantation The C57BL/6 congenic BoyJ strain, carrying the CD45.1 cell surface marker, was used as recipients for BMT studies. Recipients were 7-10 weeks old at the time of irradiation and BMT. Recipients were irradiated with a dose of 1 X 9.5 Gy and 3 h later transplanted with 5x106 bone marrow cells/200 ⁇ RPMI/mouse by retro-orbital injection under anasthesia. This protocol gave a chimerism of >98% when Ppargfl/ fl LysMCre+ or controls were used as donors and >98% when Ppargfl/- Sox2Cre+ were the donors. Transplanted animals were used for experiments 3 months after receiving BMT.
- Muscle injury Mice were anaesthetized with isoflurane and 50 ⁇ of cardiotoxin (12X10-6 mol/1 in PBS) (from Latoxan) was injected in the tibialis anterior (TA) muscle. Muscles were recovered for flow cytometry analysis at day 1, 2 or 4 post-injury or for muscle histology at day 8 post-injury.
- HE muscle sections for the day 0, day 8 and day 21 PPARg MacKO vs. WT comparisons were recorded with a Nikon E800 microscope at 2 OX magnification connected to a QIMAGING camera.
- Cross-sectional area (CSA) measurement of these samples was carried out using Metamorph software and the CSAs are reported in arbituary units.
- HE muscle sections for the day 16 GDF3 KO BMT vs. WT BMT and for the day 22 PPARg KO BMT vs. WT BMT were scanned with Mirax digital slide scanner and the CSA was measured with Panoramic Viewer software. The CSAs for these latter samples are reported in ⁇ .
- necrotic/phagocytic vs. centrally nucleated myofibers was performed using the Image J software and was expressed as a percentage of the total number of myofibers.
- Necrotic myofibers were defined as pink pale patchy fibers and phagocyted myofibers were defined as pink pale fibers, which are invaded by basophil single cells (macrophages).
- Immunofluorescent detection of muscle regeneration in day 8 CTX injected muscle Tissue sections were fixed and permeabilized in ice cold acetone for 5 min and blocked for 30 minutes at 20 °C (room temperature) in PBS containing 2 % bovine serum albumin (BSA). Tissues were stained for 1 h at room temperature using a primary antibody diluted in 2 % BSA. The primary antibodies used for immunofluorescence are listed in Supplementary Table 1. In all cases, the primary antibody was detected using secondary antibodies conjugated to FITC (JIR 712-095-153) or Cy3 JIR (711-165-152). The nuclei were counter stained with 0.1-1 ⁇ g/ml Hoechst.
- Fluorescent microscopy was performed using Carl Zeiss Axio Imager Z2 microscope equipped with lasers at 488, 568 and 633 nm. Figures were analyzed and assembled using Fiji and Illustrator CS5 (Adobe). List of primary antibodies used in immunofluorescence:
- Macrophage cell culture for conditioned medium generation Macrophages were obtained from bone marrow (BM) precursor cells. Briefly, total BM was obtained from mice by flushing femurs and tibiae bone marrow with DMEM. Cells were cultured in DMEM medium containing 20% FBS and 30% conditioned medium of L929 cell line (enriched in CSF-1) for 7 days. Macrophages were seeded (at 50000 cell/cm2 for all experiments) and were activated with IFNy (50 ng/ml) and IL4 (10 ng/ml) to obtain Ml and M2 macrophages, respectively, in DMEM containing 10% FBS medium for 3 days. After washing steps, DMEM serum-free medium was added for 24 h, recovered and centrifugated to obtain macrophage-conditioned medium.
- BM bone marrow
- MPC Myogenic precursor cell culture.
- Murine MPCs were obtained from TA muscle and cultured using standard conditions in DMEM/ F12 (Gibco Life Technologies) containing 20% FBS and 2% G/Ultroser (Pall Inc). Briefly, TA muscles of young mice were opened and cleared of nerves/blood vessels/fascia etc. Muscle preparations were lightly digested with collagenase and the resulting cells were plated then serially
- P117750 expanded.
- MPCs were seeded at 10000 cell/cm2 on matrigel (1/10) and incubated for 1 day with macrophage-conditioned medium + 2.5% FBS or with 2.5% FBS medium containing GDF3 mouse recombinant protein (300 ng/ml; R&D 958-G3-010). Cells were then incubated with anti-ki67 antibodies (15580 Abeam), which were subsequently visualized using cy3-conjugated secondary antibodies (Jackson Immunoresearch Inc).
- MPCs were seeded at 30000 cell/cm2 on matrigel (1/10) and incubated for 3 days with macrophage-conditioned medium containing 2% horse serum or with 2% horse serum medium containing GDF3 mouse recombinant protein (300 ng/ml; R&D). Cells were then incubated with anti-desmin antibodies (32362 Abeam), in combination with a cy3-conjugated secondary antibody (Jackson Immunoresearch Inc).
- Phagocytosis assay BMDM cells were generated as described earlier in this section. BMDMs were harvested with trypsin and careful scraping, washed twice in PBS and then stained with the lipophilic fluorescent dye CellVue (Sigma) according to the manufacturer's recommendation. Stained BMDMs were replated and left to recuparate for one day in DMEM medium. C2C12 cells were cultured in DMEM containing 10% FBS. Cells were harvested, washed and stained with the lipophilic fluorescent dye PKH67 (Sigma). Stained C2C12 cells were washed extensively and then heat killed at 55°C for 60 min. Heat killed C2C12 cells were added to BMDM cultures at 2:1 ratio and phagocytosis was commence at 37°C or 4°C (controls). Cells were harvested by scraping after 1 h and fluorescent intensity was detected with a FACScalibur instrument.
- Fusion index for myogenic cells was calculated as the number of nuclei within myotubes divided by the total number of nuclei, nuclei number being estimated using the Image J software.
- Ly6C+ F4/801ow macrophages, Ly6C- F4/80+ macrophages and Ly6Cmid F4/80- neutrophils were sorted. In each experiment, both genotypes were parallelly processed to minimize experimental variation. Cells were analyzed and/or sorted with a BD FACSAria III sorter.
- RNA isolation from sorted MFs were sorted from day 1, 2 and 4 post-injury muscles with a
- Microarray analysis of muscle macrophages Global expression pattern was analyzed on Affymetrix GeneChip Mouse Gene 1.0 ST arrays. Ambion WT Expression Kit (Life Technologies, Hungary) and GeneChip WT Terminal Labeling and Control Kit (Affymetrix) were used for amplifying and labeling 150 ng of total
- RT-qPCR Transcript quantification was performed by quantitative real-time RT (reverse transcriptase) PCR (polymerase chain reaction) using SYBR Green assays [Apoldl, Hebpl and Plxndl) or PrimeTime assays from IDT (Gd/3 and Pparg). Primer sequences and Taqman probes or PrimeTime assay IDs used in transcript quantification are available upon request. RT-qPCR results were analyzed with the standard delta Ct method and results were normalized to the expression of ActB.
- Macrophage cell culture for ChIP Macrophages were obtained from bone marrow (BM) precursor cells. Briefly, total BM was obtained from mice by flushing femurs and tibiae bone marrow with DMEM. Cells were RBC lysed with ACK solution and then plated on non-tissue culture grade plates then cultured in DMEM medium containing 20% FBS and 30% conditioned medium of L929 cell line (enriched in CSF-1) for 6 days. Macrophages were harvested from the culture plates and ChIP was carried out.
- BM bone marrow
- DMEM bone marrow
- ChIP ChIP immunoprecipitation: Cells were double crosslinked with 0,002M DSG (Sigma) for 30 minutes and then with 1% formaldehyde (Sigma) for 10 minutes. Nuclei were isolated with ChIP Lysis Buffer (1% Triton x-100, 0.1% SDS, 150 mM NaCl, ImM EDTA, and 20 mM Tris, pH 8.0) then chromatin were sonicated (also in ChIP Lysis Buffer) with Diagenode Bioruptor to generate 200-1000 bp fragments.
- ChIP Lysis Buffer 1% Triton x-100, 0.1% SDS, 150 mM NaCl, ImM EDTA, and 20 mM Tris, pH 8.0
- Chromatin was diluted in ChIP Lysis buffer and immunoprecipitated with antibodies against pre-immune IgG (Millipore, 12-370), (pan) RXR (sc-774 Santa Cruz Biotechnology) and PPAR gamma (Perseus #PP-A3409A). Chromatin antibody complexes were precipitated with Protein A coated paramagnetic beads (Life Technologies).
- Bioinformatic analysis of the active enhancers around the Gdf3 and AngptI4 locus Primary analysis of the raw sequence reads has been carried out using our ChlPseq analysis command line pipeline. Alignment to the mm9 assembly of the mouse genome was done by the Burrows-Wheeler Alignment (BWA) tool. Genome coverage (bedgraph) files were generated by makeTagDirectory and makeUCSCfile.pl (HOMER) and were used for visualization with IGV2. Putative DR1 elements (reaching score 9) were determined by annotatePeaks.pl (HOMER) using the RXR and PPARg motif matrices of HOMER. The following datasets were used for the identification of active enhancers:
- Tibialis anterior was removed from mice injected intramuscularly with cardiotoxin (CTX) at experimental time points and homogenized in RIPA buffer.
- CTX cardiotoxin
- CD45+/- cell populations were isolated from whole TA muscle using MACS Micro Magnetic Bead Separation system (Bergisch Gladbach, Germany). Cell populations were collected and lysed in RIPA buffer. Protein concentrations were determined by Qubit 2.0 Fluorometer Protein Assay (Life Technologies, Carlsbad, CA). Protein samples were prepared for SDS-PAGE with 2X Laemmli Sample Buffer (Bio-Rad, Hercules, CA) at a 1 mg/ml concentration.
- SDS-PAGE was completed using 4-20% Mini Protean TGX gels (Bio-Rad, Hercules, CA) at 110 volts for 1 hour. The SDS-PAGE gel was then transferred onto PVDF membrane (Thermo Fisher, Waltham, MA) at 0.35 amps for 1-2 hours at 4°C. Membranes were blocked in 5% BSA in TBS-T at room temperature for >1 hour. GDF3 was targeted using rabbit monoclonal Anti-GDF3 primary antibody (abl09617, Abeam, Cambridge, MA) at 1:1,000 dilution in 5% BSA/TBS-T overnight at 4°C.
- Anti-GAPDH mouse monoclonal primary antibody (AM4300, Ambion, Carlsbad, CA) was used as a protein loading control at 1:10,000 - 1:20,000 dilution in 5% BSA/TBST overnight at 4°C. Membranes were washed 3X with TBS-T for 5 minutes each for a total of 15 minutes. Goat Anti-Rabbit HRP secondary antibody was used for the detection of GDF3 at 1:10,000 dilution in 5%BSA/TBS- T at room temperature for 1 hour.
- Anti-Mouse HRP secondary (Cell Signaling, 7076S) and Donkey Anti- Mouse Alexa Fluor 680 secondary (abl75774) antibodies were used for the detection of GAPDH at 1:40,000 dilution at room temperature for 1 hour.
- Membranes were washed 3X with TBS-T for 5 minutes each for a total of 15 minutes, followed by 2 washes in TBS for 5 minutes.
- Super Signal West Pico Kit allowed for ECL visualization of the blot on Hyblot CL Film (Denville, E3018).
- MPCs Primary myoblast differentiation for RNA-Seq: MPCs were seeded at 30000 cell/cm2 on matrigel (1/10) in full medium. Medium was replaced with differentiation medium containing 2% horse serum 6h later and cells were cultured overnight. Next morning +/- 150ng/ml recombinant GDF3 was added to the cultures and differentiating cells were harvested in 24h (referred to as "day 1 cells" in the manuscript).
- RNA sequencing (RNA-Seq) library preparation for myoblast gene expression analysis cDNA library for RNA-Seq was generated from ⁇ g total RNA using TruSeq RNA Sample Preparation Kit (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. Briefly, poly-A tailed RNAs were purified by oligodT conjugated magnetic beads and fragmented on 94 C degree for 8 minutes, then 1st strand cDNA was transcribed using random primers and Superscript II reverse transcriptase (Lifetechnologies, Carslbad, CA, USA). Following this step, second strand cDNA were synthesized and then double stranded cDNA molecules were end repaired resulting blunt ends.
- RNA-Seq data are publicly accessible (data access: PRJNA290560/SRR2136645).
- Tissue regeneration requires inflammatory and reparatory activity of macrophages (MOs).
- MOs detect and eliminate the damaged tissue and subsequently promote regeneration. This dichotomy requires the switch of the effector functions of MOs coordinated with other cell types inside the injured tissue.
- the gene regulatory events supporting the sensory and effector functions of MOs involved in tissue repair are not well understood.
- PPARy the lipid activated transcription factor, PPARy is required for proper skeletal muscle regeneration acting in repair MOs.
- PPARy controls the expression of the TGF0 family member, GDF3, which in turn regulates the restoration of skeletal muscle integrity by promoting muscle progenitor cell differentiation.
- GDF3 the TGF0 family member
- P117750 effector protein acting on myoblasts and serving as an exclusively macrophage-derived regeneration factor in tissue repair.
- ⁇ PPARy is required for skeletal muscle regeneration and for primary myotube formation in vitro. PPARy regulates the expression of GDF3 primarily in muscle infiltrating LyC6- repair MOs.
- the GDF3 locus has multiple PPAREkRXR heterodimer bound active enhancers. GDF3 is needed for proper muscle regeneration and enhances differentiation of primary myoblasts
- Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. Journal of immunology (Baltimore, Md : 1950) 180, 1179-1188.
- Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nature cell biology 12, 153- 163.
- Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312. Lemos, D.R., Babaeijandaghi, F., Low, M., Chang, C.K., Lee, S.T., Fiore, D., Zhang, R.H., Natarajan, A, Nedospasov, S.A., and Rossi, F.M. (2015). Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nature medicine 21, 786-794.
- GDF3 a BMP inhibitor, regulates cell fate in stem cells and early embryos. Development 133, 209-216.
- GDF3 is a BMP inhibitor that can activate Nodal signaling only at very high doses. Developmental biology 325, 43-48.
- Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proceedings of the National Academy of Sciences of the United States of America 83, 8206-8210.
- CTCF and cohesin linking gene regulatory elements with their targets.
- Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116-1120.
- Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832-844.
- Latent enhancers activated by stimulation in differentiated cells. Cell 152, 157-171.
- a SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437, 759-763.
- Rapalino 0., Lazarov-Spiegler, 0., Agranov, E., Velan, G.J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., et al (1998). Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nature medicine 4, 814-821.
- STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity 33, 699-712.
- Monocyte/Macrophage-derived IGF-1 Orchestrates Murine Skeletal Muscle Regeneration and Modulates Autocrine Polarization. Molecular therapy : the journal of the American Society of Gene Therapy 23, 1189-1200.
- PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
- PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation.
- Biochimica et biophysica acta 1812, 1007-1022.
- Tissue LyC6- macrophages are generated in the absence of circulating LyC6- monocytes and Nur77 in a model of muscle regeneration. Journal of immunology (Baltimore, Md : 1950) 191, 5695-5701.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne la régulation par PPARγ de l'expression de GDF3, membre de la famille du TGFß, qui régule à son tour la restauration de l'intégrité des muscles squelettiques en favorisant la différenciation des cellules progénitrices musculaires. Ainsi, l'invention porte sur GDF3 utilisé en tant que protéine effectrice extrinsèque sécrétée agissant sur des myoblastes et servant exclusivement de facteur de régénération dérivé de macrophages dans la réparation des tissus. L'invention concerne également un composé GDF3 utilisé dans le traitement d'un patient présentant une affection ou une maladie associée à une déficience musculaire, ledit patient ayant besoin d'une différenciation musculaire, ou un composé GDF3 utilisé dans l'amélioration de la régénération ou de la différenciation musculaire d'un patient en ayant besoin, ainsi que des compositions pharmaceutiques destinées à être utilisées dans ces traitements.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/HU2016/050003 WO2016120652A1 (fr) | 2015-01-30 | 2016-02-01 | Différenciation de muscle |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUP1500038 | 2015-01-30 | ||
HUP1500038 | 2015-01-30 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2016120647A2 true WO2016120647A2 (fr) | 2016-08-04 |
WO2016120647A3 WO2016120647A3 (fr) | 2016-11-17 |
WO2016120647A4 WO2016120647A4 (fr) | 2017-01-26 |
Family
ID=56497804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2015/050019 WO2016120647A2 (fr) | 2015-01-30 | 2015-11-30 | Régénération musculaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016120647A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115386539A (zh) * | 2021-05-18 | 2022-11-25 | 南京大学 | 胸腺细胞在培养肌肉干细胞中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072715A2 (fr) | 2002-02-21 | 2003-09-04 | Wyeth | Proteine contenant un domaine de follistatine |
WO2008030706A2 (fr) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anticorps anti-myostatine |
WO2010083034A1 (fr) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Procédés permettant d'augmenter l'adiponectine |
WO2014000042A1 (fr) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | Compositions et procédés pour modifier des ligands de la famille du tgf-β |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
-
2015
- 2015-11-30 WO PCT/HU2015/050019 patent/WO2016120647A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072715A2 (fr) | 2002-02-21 | 2003-09-04 | Wyeth | Proteine contenant un domaine de follistatine |
WO2008030706A2 (fr) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anticorps anti-myostatine |
WO2010083034A1 (fr) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Procédés permettant d'augmenter l'adiponectine |
WO2014000042A1 (fr) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | Compositions et procédés pour modifier des ligands de la famille du tgf-β |
Non-Patent Citations (55)
Title |
---|
"Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges", April 2013 |
ARNOLD, L.; HENRY, A.; PORON, F.; ABA-AMER, Y.; VAN ROOIJEN, N.; PLONQUET, A.; GHERARDI, R.K.; CHAZAUD, B.: "Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 204, 2007, pages 1057 - 1069 |
BENTZINGER, C.F.; WANG, Y.X.; DUMONT, N.A.; RUDNICKI, M.A.: "Cellular dynamics in the muscle satellite cell niche.", EMBO REPORTS, vol. 14, 2013, pages 1062 - 1072 |
BRYER, S.C.; FANTUZZI, G.; VAN ROOIJEN, N; KOH, T.J.: "Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration", JOURNAL OF IMMUNOLOGY, vol. 180, 2008, pages 1179 - 1188 |
BURZYN, D.; KUSWANTO, W.; KOLODIN, D.; SHADRACH, J.L.; CERLETTI, M.; JANG, Y.; SEFIK, E.; TAN, T.G.; WAGERS, A.J.; BENOIST, C. ET: "A special population of regulatory T cells potentiates muscle repair", CELL, vol. 155, 2013, pages 1282 - 1295, XP055243203, DOI: doi:10.1016/j.cell.2013.10.054 |
CHAZAUD, B.: "Macrophages: supportive cells for tissue repair and regeneration", IMMUNOBIOLOGY, vol. 219, 2014, pages 172 - 178, XP028827102, DOI: doi:10.1016/j.imbio.2013.09.001 |
CHEN C; WARE SM; SATO A; HOUSTON-HAWKINS DE; HABAS R; MATZUK MM; SHEN MM; BROWN CW: "The Vgl-related protein Gdf3 acts in a Nodal signaling pathway in the pre-gastrulation mouse embryo", DEVELOPMENT, vol. 133, no. 2, January 2006 (2006-01-01), pages 319 - 29 |
CHEN, J.L.; WALTON, K.L.; AL-MUSAWI, S.L.; KELLY, E.K.; QIAN, H.; LA, M.; LU, L.; LOVRECZ, G.; ZIEMANN, M.; LAZARUS, R. ET AL.: "Development of novel activin-targeted therapeutics", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 23, 2015, pages 434 - 444 |
CLAUSEN, B.E.; BURKHARDT, C.; REITH, W.; RENKAWITZ, R.; FORSTER, I.: "Conditional gene targeting in macrophages and granulocytes using LysMcre mice", TRANSGENIC RESEARCH, vol. 8, 1999, pages 265 - 277 |
COUTEAUX, R.; MIRA, J.C.; D'ALBIS, A.: "Regeneration of muscles after cardiotoxin injury. I", CYTOLOGICAL ASPECTS. BIOLOGY OF THE. CELL / UNDER THE AUSPICES OF THE EUROPEAN CELL BIOLOGY, vol. 62, 1988, pages 171 - 182, XP025207468, DOI: doi:10.1016/0248-4900(88)90034-2 |
DADGAR, S.; WANG, Z.; JOHNSTON, H.; KESARI, A.; NAGARAJU, K.; CHEN, Y.W.; HILL, D.A.; PARTRIDGE, T.A.; GIRI, M.; FREISHTAT, R.J. E: "Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy", THE JOURNAL OF CELL BIOLOGY, vol. 207, 2014, pages 139 - 158 |
DANIEL, B.; NAGY, G.; HAH, N.; HORVATH, A.; CZIMMERER, Z.; POLISKA, S.; GYURIS, T.; KEIRSSE, J.; GYSEMANS, C.; VAN GINDERACHTER, J: "The active enhancer network operated by liganded RXR supports angiogenic activity in macrophages.", GENES & DEVELOPMENT, vol. 28, 2014, pages 1562 - 1577 |
DUFFIELD, J.S.; FORBES, S.J.; CONSTANDINOU, C.M.; CLAY, S.; PARTOLINA, M.; VUTHOORI, S.; WU, S.; LANG, R.; IREDALE, J.P.: "Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, 2005, pages 56 - 65 |
GAUTIER, E.L.; CHOW, A.; SPANBROEK, R.; MARCELIN, G.; GRETER, M.; JAKUBZICK, C.; BOGUNOVIC, M.; LEBOEUF, M.; VAN ROOIJEN, N.; HABE: "Systemic analysis of PPARgamma in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity", JOURNAL OF IMMUNOLOGY, vol. 189, 2012, pages 2614 - 2624 |
GODWIN, J.W.; PINTO, A.R.; ROSENTHAL, N.A.: "Macrophages are required for adult salamander limb regeneration", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 110, 2013, pages 9415 - 9420 |
HEREDIA, J.E.; MUKUNDAN, L.; CHEN, F.M.; MUELLER, A.A.; DEO, R.C.; LOCKSLEY, R.M.; RANDO, T.A.; CHAWLA, A.: "Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration", CELL, vol. 153, 2013, pages 376 - 388, XP028547929, DOI: doi:10.1016/j.cell.2013.02.053 |
HIDESTRAND, M.; RICHARDS-MALCOLM, S.; GURLEY, C.M.; NOLEN, G.; GRIMES, B.; WATERSTRAT, A.; ZANT, G.V.; PETERSON, C.A.: "Sca-1-expressing nonmyogenic cells contribute to fibrosis in aged skeletal muscle", THE JOURNALS OF GERONTOLOGY SERIES A, BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, vol. 63, 2008, pages 566 - 579 |
JOE, A.W.; YI, L.; NATARAJAN, A.; LE GRAND, F.; SO, L.; WANG, J.; RUDNICKI, M.A.; ROSSI, F.M.: "Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis", NATURE CELL BIOLOGY, vol. 12, 2010, pages 153 - 163, XP055082083, DOI: doi:10.1038/ncb2015 |
KAIKKONEN, M.U.; SPANN, N.J.; HEINZ, S.; ROMANOSKI, C.E.; ALLISON, K.A.; STENDER, J.D.; CHUN, H.B.; TOUGH, D.F.; PRINJHA, R.K.; BE: "Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.", MOLECULAR CELL, vol. 51, 2013, pages 310 - 325, XP028692908, DOI: doi:10.1016/j.molcel.2013.07.010 |
KHUDYAKOV, YURY E.: "Medicinal Protein Engineering", 1 December 2008, CRC PRESS |
LACH-TRIFILIEFF, E.; MINETTI, G.C.; SHEPPARD, K.; IBEBUNJO, C.; FEIGE, J.N.; HARTMANN, S.; BRACHAT, S.; RIVET, H.; KOELBING, C.; M: "An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy", MOLECULAR AND CELLULAR BIOLOGY, vol. 34, 2014, pages 606 - 618, XP002732136, DOI: doi:10.1128/MCB.01307-13 |
LAFLAMME, M.A.; MURRY, C.E.: "Heart regeneration", NATURE, vol. 473, 2011, pages 326 - 335, XP055163863, DOI: doi:10.1038/nature10147 |
LAVIN, Y.; WINTER, D.; BLECHER-GONEN, R.; DAVID, E.; KEREN-SHAUL, H.; MERAD, M.; JUNG, S.; AMIT, I.: "Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment.", CELL, vol. 159, 2014, pages 1312, XP029110667, DOI: doi:10.1016/j.cell.2014.11.018 |
LEMOS, D.R.; BABAEIJANDAGHI, F.; LOW, M.; CHANG, C.K.; LEE, S.T.; FIORE, D.; ZHANG, R.H.; NATARAJAN, A.; NEDOSPASOV, S.A.; ROSSI,: "Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors", NATURE MEDICINE, vol. 21, 2015, pages 786 - 794 |
LEVINE A; BRIVANLOU A: "GDF3, a BMP inhibitor, regulates cell fate in stem cells and early embryos", DEVELOPMENT, vol. 133, no. 2, 2006, pages 209 - 16 |
LEVINE AJ; BRIVANLOU AH.: "GDF3 at the crossroads of TGF-beta signaling", CELL CYCLE, vol. 5, no. 10, 15 May 2006 (2006-05-15), pages 1069 - 73 |
LEVINE, A.J.; BRIVANLOU, A.H.: "GDF3, a BMP inhibitor, regulates cell fate in stem cells and early embryos.", DEVELOPMENT, vol. 133, 2006, pages 209 - 216 |
LEVINE, A.J.; LEVINE, Z.J.; BRIVANLOU, A.H.: "GDF3 is a BMP inhibitor that can activate Nodal signaling only at very high doses.", DEVELOPMENTAL BIOLOGY, vol. 325, 2009, pages 43 - 48, XP025840156, DOI: doi:10.1016/j.ydbio.2008.09.006 |
MASSAGUE, J.; CHEIFETZ, S.; ENDO, T.; NADAL-GINARD, B.: "Type beta transforming growth factor is an inhibitor of myogenic differentiation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 83, 1986, pages 8206 - 8210 |
MCPHERRON, A.C.; LAWLER, A.M.; LEE, S.J.: "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member", NATURE, vol. 387, 1997, pages 83 - 90, XP002085797, DOI: doi:10.1038/387083a0 |
MERKENSCHLAGER, M.; ODOM, D.T.: "CTCF and cohesin: linking gene regulatory elements with their targets", CELL, vol. 152, 2013, pages 1285 - 1297, XP029001369, DOI: doi:10.1016/j.cell.2013.02.029 |
MOUNIER, R.; THERET, M.; ARNOLD, L.; CUVELLIER, S.; BULTOT, L.; GORANSSON, 0.; SANZ, N.; FERRY, A.; SAKAMOTO, K.; FORETZ, M. ET AL: "AMPKalphal regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration", CELL METABOLISM, vol. 18, 2013, pages 251 - 264 |
NADRA, K.; QUIGNODON, L.; SARDELLA, C.; JOYE, E.; MUCCIOLO, A.; CHRAST, R.; DESVERGNE, B.: "PPARgamma in placental angiogenesis", ENDOCRINOLOGY, vol. 151, 2010, pages 4969 - 4981 |
ODEGAARD, J.I.; CHAWLA, A.: "Alternative macrophage activation and metabolism", ANNUAL REVIEW OF PATHOLOGY, vol. 6, 2011, pages 275 - 297 |
ODEGAARD, J.I.; RICARDO-GONZALEZ, R.R.; GOFORTH, M.H.; MOREL, C.R.; SUBRAMANIAN, V.; MUKUNDAN, L.; RED EAGLE, A.; VATS, D.; BROMBA: "Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance", NATURE, vol. 447, 2007, pages 1116 - 1120 |
OKABE, Y.; MEDZHITOV, R.: "Tissue-specific signals control reversible program of localization and functional polarization of macrophages.", CELL, vol. 157, 2014, pages 832 - 844, XP028650311, DOI: doi:10.1016/j.cell.2014.04.016 |
OSTUNI, R.; PICCOLO, V.; BAROZZI, I.; POLLETTI, S.; TERMANINI, A.; BONIFACIO, S.; CURINA, A.; PROSPERINI, E.; GHISLETTI, S.; NATOL: "Latent enhancers activated by stimulation in differentiated cells", CELL, vol. 152, 2013, pages 157 - 171 |
PARISI, A.; LACOUR, F.; GIORDANI, L.; COLNOT, S.; MAIRE, P.; LE GRAND, F.: "APC is required for muscle stem cell proliferation and skeletal muscle tissue repair", THE JOURNAL OF CELL BIOLOGY, 2015 |
PASCUAL, G.; FONG, A.L.; OGAWA, S.; GAMLIEL, A.; LI, A.C; PERISSI, V.; ROSE, D.W.; WILLSON, T.M.; ROSENFELD, M.G.; GLASS, C.K.: "A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma", NATURE, vol. 437, 2005, pages 759 - 763 |
PETRIE, T.A.; STRAND, N.S.; YANG, C.T.; RABINOWITZ, J.S.; MOON, R.T.: "Macrophages modulate adult zebrafish tail fin regeneration", DEVELOPMENT, vol. 141, 2014, pages 2581 - 2591 |
PORRELLO, E.R.; MAHMOUD, A.I.; SIMPSON, E.; HILL, J.A.; RICHARDSON, J.A.; OLSON, E.N.; SADEK, H.A.: "Transient regenerative potential of the neonatal mouse heart", SCIENCE, vol. 331, 2011, pages 1078 - 1080 |
RAPALINO, 0.; LAZAROV-SPIEGLER, 0.; AGRANOV, E.; VELAN, G.J.; YOLES, E.; FRAIDAKIS, M.; SOLOMON, A.; GEPSTEIN, R.; KATZ, A.; BELKI: "Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats", NATURE MEDICINE, vol. 4, 1998, pages 814 - 821 |
SARTORI, R.; SCHIRWIS, E.; BLAAUW, B.; BORTOLANZA, S.; ZHAO, J.; ENZO, E.; STANTZOU, A.; MOUISEL, E.; TONIOLO, L.; FERRY, A. ET AL: "BMP signaling controls muscle mass.", NATURE GENETICS, vol. 45, 2013, pages 1309 - 1318 |
SHEN, J.J.; HUANG, L.; LI, L.; JORGEZ, C.; MATZUK, M.M.; BROWN, C.W.: "Deficiency of growth differentiation factor 3 protects against diet-induced obesity by selectively acting on white adipose", MOLECULAR ENDOCRINOLOGY, vol. 23, 2009, pages 113 - 123 |
SZANTO, A.; BALINT, B.L.; NAGY, Z.S.; BARTA, E.; DEZSO, B.; PAP, A.; SZELES, L.; POLISKA, S.; OROS, M.; EVANS, R.M. ET AL.: "STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells", IMMUNITY, vol. 33, 2010, pages 699 - 712 |
TONKIN, J.; TEMMERMAN, L.; SAMPSON, R.D.; GALLEGO-COLON, E.; BARBERI, L.; BILBAO, D.; SCHNEIDER, M.D; MUSARO, A; ROSENTHAL, N.: "Monocyte/Macrophage-derived IGF-1 Orchestrates Murine Skeletal Muscle Regeneration and Modulates Autocrine Polarization", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, vol. 23, 2015, pages 1189 - 1200 |
TONTONOZ, P.; NAGY, L.; ALVAREZ, J.G.; THOMAZY, V.A.; EVANS, R.M.: "PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL", CELL, vol. 93, 1998, pages 241 - 252, XP000986023, DOI: doi:10.1016/S0092-8674(00)81575-5 |
UEZUMI, A.; FUKADA, S.; YAMAMOTO, N.; TAKEDA, S.; TSUCHIDA, K.: "Mesenchymal progenitors distinct from satellite cells Contribute to ectopic fat cell formation in skeletal muscle", NATURE CELL BIOLOGY, vol. 12, 2010, pages 143 - 152, XP055110152, DOI: doi:10.1038/ncb2014 |
VARGA, T.; CZIMMERER, Z.; NAGY, L.: "PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation", BIOCHIMICA ETBIOPHYSICA ACTA, vol. 1812, 2011, pages 1007 - 1022 |
VARGA, T.; MOUNIER, R.; GOGOLAK, P.; POLISKA, S.; CHAZAUD, B.; NAGY, L.: "Tissue LyC6- macrophages are generated in the absence of circulating LyC6- monocytes and Nur77 in a model of muscle regeneration", JOURNAL OF IMMUNOLOGY, vol. 191, 2013, pages 5695 - 5701 |
VATS, D.; MUKUNDAN, L.; ODEGAARD, J.I.; ZHANG, L.; SMITH, K.L.; MOREL, C.R.; WAGNER, R.A.; GREAVES, D.R.; MURRAY, P.J.; CHAWLA, A.: "Oxidative metabolism and PGC-lbeta attenuate macrophage-mediated inflammation", CELL METABOLISM, vol. 4, 2006, pages 13 - 24 |
WELCH, J.S.; RICOTE, M.; AKIYAMA, T.E.; GONZALEZ, F.J.; GLASS, C.K.: "PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, 2003, pages 6712 - 6717 |
YADEN, B.C.; WANG, Y.X.; WILSON, J.M.; CULVER, A.E.; MILNER, A.; DATTA-MANNAN, A.; SHETLER, P.; CROY, J.E.; DAI, G.; KRISHNAN, V.: "Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 184, 2014, pages 1152 - 1166 |
YAN, Z.; CHOI, S.; LIU, X.; ZHANG, M.; SCHAGEMAN, J.J.; LEE, S.Y.; HART, R.; LIN, L.; THURMOND, F.A.; WILLIAMS, R.S.: "Highly coordinated gene regulation in mouse skeletal muscle regeneration", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, 2003, pages 8826 - 8836, XP002518537, DOI: doi:10.1074/JBC.M209879200 |
YIN, H.; PRICE, F.; RUDNICKI, M.A.: "Satellite cells and the muscle stem cell niche.", PHYSIOLOGICAL REVIEWS, vol. 93, 2013, pages 23 - 67, XP055356555, DOI: doi:10.1152/physrev.00043.2011 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115386539A (zh) * | 2021-05-18 | 2022-11-25 | 南京大学 | 胸腺细胞在培养肌肉干细胞中的用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2016120647A4 (fr) | 2017-01-26 |
WO2016120647A3 (fr) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Berglund et al. | Microglial autophagy–associated phagocytosis is essential for recovery from neuroinflammation | |
Varga et al. | Macrophage PPARγ, a lipid activated transcription factor controls the growth factor GDF3 and skeletal muscle regeneration | |
Takahashi et al. | TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis | |
Shin et al. | DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates | |
JP6450673B2 (ja) | 幹細胞微粒子 | |
TWI629995B (zh) | 治療成骨不全之方法 | |
Galdo et al. | Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis | |
US20210052657A1 (en) | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases | |
Jin et al. | Extracellular vesicles derived from human dental pulp stem cells promote osteogenesis of adipose-derived stem cells via the MAPK pathway | |
JP2015529450A (ja) | 幹細胞微粒子 | |
Paris et al. | Smad4 restricts differentiation to promote expansion of satellite cell derived progenitors during skeletal muscle regeneration | |
Fiore et al. | Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells | |
Farini et al. | Defective dystrophic thymus determines degenerative changes in skeletal muscle | |
Hou et al. | Exosomal miR‐128‐3p reversed fibrinogen‐mediated inhibition of oligodendrocyte progenitor cell differentiation and remyelination after cerebral ischemia | |
WO2016120647A2 (fr) | Régénération musculaire | |
Yang et al. | Cardioprotective effect of NRG-4 gene expression on spontaneous hypertension rats and its mechanism through mediating the activation of ErbB signaling pathway | |
Kawai et al. | Prevention of skeletal muscle atrophy in vitro using anti-ubiquitination oligopeptide carried by atelocollagen | |
Mastrandrea | Immunotherapy in atopic dermatitis | |
Lynn et al. | SMAD signaling in the airways of healthy rhesus macaques versus rhesus macaques with asthma highlights a relationship between inflammation and bone morphogenetic proteins | |
WO2016120652A1 (fr) | Différenciation de muscle | |
US20240131075A1 (en) | Use of mbv for treating autoimmune disease | |
JP2024505886A (ja) | セクレトームを調製する方法及びその使用 | |
WO2013040391A2 (fr) | Nouveaux marqueurs de surface pour tissus adipeux | |
Nackiewicz et al. | Islet macrophages are the primary islet source of IGF-1 and improve glucose homeostasis following pancreatic beta-cell death | |
Fazazi et al. | Myelin-reactive B cells exacerbate the severity of CD4+ T cell-driven CNS autoimmunity in an IL-23-dependent manner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15879269 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15879269 Country of ref document: EP Kind code of ref document: A2 |